It was confirmed for the first time in the IPASS that EGFR mutations in exon 19 and 21 are the strongest predictive biomarkers for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel12. The gene discussed is EGFR; the disease is neoplasm.